Gabexate mesilate is a synthetic serine proteinase inhibitor, which also inhibits several
coagulation factors. Gabexate mesilate has still an inhibitory capacity on the coagulation
cascade in the abscence of antithrombin Ⅲ , which heparin does not. This is a clinical
trial of Gabexate mesilate for the treatment of disseminated intrevascular coagulation
associated with several underlying disorders.
Studied patients consisted of 117 children with DIC who were admitted to the
Pediatric Department of Severance Hospital from January 1985 to May 1990. Three
groups were consisted with Gabexate mesilate treated group (37 patients), heparin
treated group (24 patients) and control group (56 patients).
The results were as follows.
1. There were no statistically significant differences among three groups in age, sex
and initial laboratory findings.
2. Infection, especially sepsis, was the most common underlying disease among studied
groups.
3. The laboratory findings of 7th day after treatment showed significantly
improvement of PT, PTT, fibrinogen and FDP in Gabexate mesilate treated group
(p<0.05).
4. Duration of laboratory finding to be normalized after treatment showed significantly
shortening of normalized interval of PT, PTT in Gabexate mesilate treated group
(p<0.05). There was significantly shortening of normalized interval of fibrinogen and
platelet count in Gabexate mesilate treated group and heparin reacted group(p<0.05).
5. In clinical outcome of DIC patients, 25 out of 37 patient (67.5% ) in Gabexate
mesilate treated group, 11 out of 24 patient (45.6%) in heparin treated group, 9 out of 56
patient (16%) in control group were improved.
6. No remarkable side effects of Gabexate mesilate were observed.
|